China's HighLight to exit US-based biotech player Bonti
Chinese healthcare-focused GP HighLight Capital is set to exit its position in US-based biotechnology company Bonti after Allergan agreed to acquire the business for $195 million, plus additional payments if certain development targets are met.
HighLight first backed Bonti in early 2017, leading the extension to a Series B round worth $11.7 million in total. It then led a $15.5 million Series C at the beginning of this year. The company already...
More on Greater China
Latest News
HESTA backs PEP-owned Australia software business
HESTA has acquired a A$120 million ($85 million) equity stake in Australian enterprise software and IT services provider Citadel, following its merger with medical practice software specialist Genie Solutions.
CVC exits Malaysia snacks business to Universal Robina
CVC Capital Partners has agreed to sell Malaysia-based snack foods producer Munchy Food Industries to Universal Robina Corporation (URC) – a branded consumer food and beverage business in the Philippines – for MYR1.93 billion ($454 million).
Secondaries supply-demand mismatch most extreme in Asia - AVCJ Forum
There is not enough capital in Asia to address the number of secondary opportunities – mirroring the situation globally – with investors claiming to have more transaction choices than ever before.
China GPU chip designer secures $313m Series A
Moore Threads, a Chinese chip designer established 13 months ago by a team from Nvidia, has closed Series A at RMB2 billion ($313 million) led by Shanghai Guosheng Capital, 5Y Capital, and a BOC International fund.